CPT® Code 38242

Allogeneic lymphocyte infusions involve the transfer of lymphocytes from a donor to a recipient, specifically targeting patients who have previously undergone an allogeneic hematopoietic progenitor cell (HPC) transplant. This procedure is particularly relevant for individuals who subsequently develop hematologic malignancies, such as leukemia or lymphoma, after their initial transplant. The term "allogeneic" refers to the use of donor cells, which are derived from a genetically different individual, as opposed to autologous cells that come from the same patient. The process begins with a leukopheresis procedure, which is a separate and reportable intervention performed on the original HPC donor to collect the necessary lymphocytes. Once harvested, these donor lymphocytes can be infused into the recipient either immediately or after being preserved through freezing. The primary goal of this infusion is to elicit a robust graft versus leukemia or lymphoma response, which aims to target and eliminate the malignant cells present in the recipient's body. This therapeutic approach is critical in enhancing the patient's immune response against their cancer, thereby improving their overall prognosis and potential for recovery.